Antivenom: The most cost-effective treatment in the world?

被引:40
作者
Brown, N. [1 ,2 ]
Landon, J. [3 ,4 ]
机构
[1] Univ Melbourne, Dept Pharmacol, Australian Venom Res Unit, Melbourne, Vic 3010, Australia
[2] Univ Cambridge, Inst Biotechnol, Cambridge, England
[3] Queen Mary Univ LDndon, London, England
[4] St Bartholomews Hosp, London, England
基金
英国生物技术与生命科学研究理事会; 英国工程与自然科学研究理事会;
关键词
Antivenom; Cost-effective; Snakebite; DALY; Economic; HIV/AIDS; AFRICA; BITE;
D O I
10.1016/j.toxicon.2010.02.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antivenom is the only effective treatment for envenoming by snakes, scorpions and other venomous creatures. Unfortunately, supplies of this life-saving drug in many countries are critically low, and the tragic consequence of untreated envenoming exacts a chronic humanitarian and economic burden on those communities affected. This neglected health crisis struggles to compete with higher profile illnesses for recognition, research attention and funding. Sound strategies to improve the provision of antivenoms repeatedly fail because of an inability to attract the requisite financial investment. In the highly competitive international health landscape, the greatest challenge for stakeholders is to demonstrate that antivenom constitutes an affordable, cost-effective and worthwhile investment of healthcare resources. Recent collaborations in the UK. Africa and South America, have proven that lowering the production costs of antivenom to affordable levels is sustainable. A simple healthcare-economic calculation can be used to demonstrate the superior cost-effectiveness of antivenoms in preventing death and disability. These advances may lead to antivenom becoming one of the most cost-effective treatments available to modern medicine, and provides strong justification for its inclusion in international health funding initiatives. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1405 / 1407
页数:3
相关论文
共 11 条
[1]  
BRENT RJ, 2009, APPL ECON, P1466
[2]   The economics of HIV/AIDS in low-income countries: The case for prevention [J].
Canning, David .
JOURNAL OF ECONOMIC PERSPECTIVES, 2006, 20 (03) :121-142
[3]   Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence [J].
Creese, A ;
Floyd, K ;
Alban, A ;
Guinness, L .
LANCET, 2002, 359 (9318) :1635-1642
[4]   Envenoming after carpet viper (Echis ocellatus) bite during pregnancy:: timely use of effective antivenom improves maternal and foetal outcomes [J].
Habib, A. G. ;
Abubakar, S. B. ;
Abubakar, I. S. ;
Larnyang, S. ;
Durfa, N. ;
Nasidi, A. ;
Yusuf, P. O. ;
Garnvwa, J. ;
Theakston, R. D. G. ;
Salako, L. ;
Warrell, D. A. .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2008, 13 (09) :1172-1175
[5]   Achieving the millennium development goals for health - Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries [J].
Hogan, DR ;
Baltussen, R ;
Hayashi, C ;
Lauer, JA ;
Salomon, JA .
BRITISH MEDICAL JOURNAL, 2005, 331 (7530) :1431-1435
[6]   HIV prevention before HAART in sub-Saharan Africa [J].
Marseille, E ;
Hofmann, PB ;
Kahn, JG .
LANCET, 2002, 359 (9320) :1851-1856
[7]  
MEIER J, 1995, HDB CLIN TOXICOLOGY, P472
[8]   Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis [J].
Rushby, JF ;
Hanson, K .
HEALTH POLICY AND PLANNING, 2001, 16 (03) :326-331
[9]   Crisis in snake antivenom supply for Africa [J].
Theakston, RDG ;
Warrell, DA .
LANCET, 2000, 356 (9247) :2104-2104
[10]  
WARRELL DA, 1977, Q J MED, V46, P33